UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

American journal of hypertension, 1997-07, Vol.10 (7), p.705-713

1997

Volltextzugriff (PDF)

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

American journal of hypertension, 2000-08, Vol.13 (8), p.899-906

2000

Volltextzugriff (PDF)

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Volltextzugriff (PDF)

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-09, Vol.16 (9), p.2521-2527

2005

Volltextzugriff (PDF)

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-08, Vol.16 (8), p.2247-2250

2005

Volltextzugriff (PDF)

Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study

Hypertension (Dallas, Tex. 1979), 1998-12, Vol.32 (6), p.989-997

1998

Volltextzugriff (PDF)

BETA-BLOCKERS AND URIC-ACID EXCRETION

The Lancet (British edition), 1978-11, Vol.312 (8100), p.1160-1160

1978

Volltextzugriff (PDF)

Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection

Journal of chromatography, 1979, Vol.162 (1), p.81-87

1979

Volltextzugriff (PDF)

Pharmacological hypertension therapy

Ugeskrift for læger, 2009-06, Vol.171 (24), p.2022

2009

Volltextzugriff (PDF)

Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls: a proximal tubular effect?

European journal of clinical pharmacology, 1987-01, Vol.32 (2), p.121-126

1987

Volltextzugriff (PDF)

The experimental use of calcium antagonists in the treatment of arterial hypertension

Postgraduate medical journal, 1983, Vol.59 Suppl 2, p.84-90

Lederballe Pedersen, O

1983

Volltextzugriff (PDF)

BETA-BLOCKER WITHDRAWAL SYNDROME?

The Lancet (British edition), 1979-03, Vol.313 (8115), p.554-555

1979

Volltextzugriff (PDF)

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Expert opinion on emerging drugs, 2005-11, Vol.10 (4), p.729-745

2005

Volltextzugriff (PDF)

Treatment with Verapamil Reduces Blood Pressure and Tends to Normalize Vascular Responsiveness and Ion Transport in the Spontaneously Hypertensive Rat

Journal of cardiovascular pharmacology, 1982, Vol.4 Suppl 3 (Supplement 3), p.S298-S298

1982

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.23, p.995-1003

2002

Volltextzugriff (PDF)

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study: The LIFE Substudy

Journal of human hypertension, 2004, Vol.18 (6), p.381-389

2004

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.23, p.1004-1010

2002

Volltextzugriff (PDF)

Wirkung von Digoxin auf die Blutgefäße

Deutsche medizinische Wochenschrift, 1980, Vol.105 (37), p.1269-1270

1980

Volltextzugriff (PDF)

Body build and risk of cardiovascular events in hypertension:: The life study

JOURNAL OF HYPERTENSION, 2005, Vol.23, p.S133

2005

Volltextzugriff (PDF)

EFFECTS OF NIFEDIPINE ON BLOOD PRESSURE, REGIONAL HEMODYNAMICS, PLASMA RENIN ACTIVITY AND PLASMA CATECHOLAMINES IN PATIENTS WITH ARTERIAL HYPERTENSION

Acta Medica Scandinavica, 1979-01, Vol.205 (S625), p.65-67

1979

Volltextzugriff (PDF)

Body build and risk of cardiovascular events in hypertension: The LIFE Study

CIRCULATION, 2004, Vol.110 (17), p.771

2004

Volltextzugriff (PDF)

H35 Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study

American journal of hypertension, 1997-04, Vol.10 (S2), p.85A-85A

1997

Volltextzugriff (PDF)

Benefits of losartan compared to atenolol in stroke prevention among patients with hypertension and left ventricular hypertrophy: The Losartan intervention for endpoint reduction in hypertension (LIFE) Study

CIRCULATION, 2003, Vol.108 (17), p.601

2003

Volltextzugriff (PDF)

Amlodipine

Ugeskrift for læger, 1991-07, Vol.153 (28), p.2021

1991

Volltextzugriff (PDF)

New-onset diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE)

CIRCULATION, 2002, Vol.106 (19), p.573

2002

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study

BETA-BLOCKERS AND URIC-ACID EXCRETION

Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection

Pharmacological hypertension therapy

Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls: a proximal tubular effect?

The experimental use of calcium antagonists in the treatment of arterial hypertension

BETA-BLOCKER WITHDRAWAL SYNDROME?

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Treatment with Verapamil Reduces Blood Pressure and Tends to Normalize Vascular Responsiveness and Ion Transport in the Spontaneously Hypertensive Rat

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study: The LIFE Substudy

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Wirkung von Digoxin auf die Blutgefäße

Body build and risk of cardiovascular events in hypertension:: The life study

EFFECTS OF NIFEDIPINE ON BLOOD PRESSURE, REGIONAL HEMODYNAMICS, PLASMA RENIN ACTIVITY AND PLASMA CATECHOLAMINES IN PATIENTS WITH ARTERIAL HYPERTENSION

Body build and risk of cardiovascular events in hypertension: The LIFE Study

H35 Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study

Benefits of losartan compared to atenolol in stroke prevention among patients with hypertension and left ventricular hypertrophy: The Losartan intervention for endpoint reduction in hypertension (LIFE) Study

Amlodipine

New-onset diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE)

Aktive Filter

Suchergebnisse filtern